Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trials (PDQ®)

Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Basic Trial Information
Trial Description
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedTissue collection/RepositoryActiveNot specifiedNCI, OtherCDR0000357586
ECOG-E3903, E3903, NCT00897767

Trial Description


RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about diagnosing cancer and determine a patient's eligibility for a treatment clinical trial. It may also help the study of cancer in the future.

PURPOSE: This laboratory study is collecting tissue samples from patients with leukemia or other blood disorders who are planning to enroll in an ECOG leukemia treatment clinical trial.

Further Study Information


  • To provide a mechanism for sample collection and submission for diagnostic review to determine eligibility of patients with suspected leukemia or related hematologic disorders for enrollment on ECOG leukemia clinical trials.
  • To obtain baseline samples for correlative studies outlined in parent clinical trials.

OUTLINE: This is a cohort, multicenter study.

Patients submit bone marrow and/or blood samples. The samples are studied to determine patients' eligibility for ECOG leukemia treatment clinical trials. Samples may be stored for future correlative studies related to ECOG treatment clinical trials.

Eligibility Criteria


  • Candidate for enrollment on an ECOG treatment clinical trial for acute or chronic leukemia
  • Suspected clinical diagnosis and protocol ID number of the treatment clinical trial under consideration must be submitted to ECOG's Leukemia Translational Studies Laboratory to ensure that the required antibody panels are used and functional assays are performed
  • Chosen ECOG treatment clinical trial must be active and accruing
  • Patient must not have begun treatment on the ECOG treatment clinical trial
  • Patient may be concurrently enrolled on this laboratory study and a treatment clinical trial if immediate treatment is medically necessary
  • If subsequent diagnostic review alters the original diagnosis, the patient will be removed from the treatment clinical trial


  • Not specified


  • See Disease Characteristics

Trial Contact Information

Trial Lead Organizations/Sponsors

Eastern Cooperative Oncology Group

National Cancer Institute

Elisabeth PaiettaStudy Chair

Trial Sites

 Medical and Surgical Specialists, LLC
 Nguyet A Le-Lindqwister Ph: 800-793-2262
 Hematology/Oncology of the North Shore at Gross Point Medical Center
 Elisabeth Paietta
 Eastern Cooperative Oncology Group
 Elisabeth M Paietta Ph: 718-904-2730
New York
 Albert Einstein Cancer Center at Albert Einstein College of Medicine
 Elisabeth Paietta
 Aultman Cancer Center at Aultman Hospital
 Elisabeth Paietta
South Dakota
  Sioux Falls
 Avera Cancer Institute
 Addison R Tolentino Ph: 800-657-4377
 Dean Hematology & Oncology Clinic
 Amit Sanyal Ph: 608-410-2700

Link to the current record.
NLM Identifer NCT00897767 processed this data on February 27, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to

Back to TopBack to Top